Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to $8.1 million.

  • InspireMD's Non-Current Assets rose 9772.45% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 9772.45%. This contributed to the annual value of $6.3 million for FY2024, which is 8042.48% up from last year.
  • As of Q3 2025, InspireMD's Non-Current Assets stood at $8.1 million, which was up 9772.45% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, InspireMD's Non-Current Assets peaked at $8.1 million during Q3 2025, and registered a low of $2.4 million during Q1 2021.
  • In the last 5 years, InspireMD's Non-Current Assets had a median value of $3.3 million in 2022 and averaged $4.0 million.
  • Per our database at Business Quant, InspireMD's Non-Current Assets tumbled by 453.15% in 2023 and then skyrocketed by 10647.27% in 2025.
  • InspireMD's Non-Current Assets (Quarter) stood at $2.6 million in 2021, then grew by 27.08% to $3.3 million in 2022, then increased by 4.72% to $3.5 million in 2023, then skyrocketed by 80.42% to $6.3 million in 2024, then increased by 28.56% to $8.1 million in 2025.
  • Its Non-Current Assets was $8.1 million in Q3 2025, compared to $7.9 million in Q2 2025 and $6.5 million in Q1 2025.